We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Alzamend Neuro Inc is an early clinical stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipe... Alzamend Neuro Inc is an early clinical stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's. Show more
false --04-30 0001677077 0001677077 2024-03-07 2024-03-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares ...
false --04-30 0001677077 0001677077 2024-02-02 2024-02-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares ...
false 0001677077 0001677077 2024-01-05 2024-01-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED...
false --04-30 2024 Q2 0001677077...
Alzamend’s recently completed Phase IIA study of AL001 in Alzheimer’s patients and healthy subjects showed a benign safety profile and identified a candidate dose that is unlikely to require...
Alzamend’s recently completed Phase IIA study of AL001 in Alzheimer’s patients and healthy subjects showed a benign safety profile and identified a candidate dose that is unlikely to require...
false 0001677077 0001677077 2023-11-16 2023-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.04 | -3.84615384615 | 1.04 | 1.1017 | 0.953601 | 40237 | 1.0195647 | CS |
4 | 0.06 | 6.3829787234 | 0.94 | 1.29 | 0.9001 | 103859 | 1.09511454 | CS |
12 | 0.06 | 6.3829787234 | 0.94 | 1.29 | 0.74 | 53262 | 1.03543743 | CS |
26 | -2.516 | -71.558589306 | 3.516 | 3.897 | 0.74 | 140306 | 1.77720706 | CS |
52 | -5.75 | -85.1851851852 | 6.75 | 11.91 | 0.74 | 161074 | 4.63334176 | CS |
156 | -434 | -99.7701149425 | 435 | 503.25 | 0.74 | 1254934 | 42.0301464 | CS |
260 | -434 | -99.7701149425 | 435 | 503.25 | 0.74 | 1254934 | 42.0301464 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions